Why the study?
Existing cardiovascular drugs are not completely successful for the management of cardiovascular disease and hypertension, necessitating the discovery and development of new drugs.
This review highlights new and emerging cardiovascular drugs that offer novel mechanisms of action for the management of hypertension and cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Current CV drugs fall short for full hypertension control; leaves open need for novel agents and confirmatory trials.
Introduction Hypertension and cardiovascular diseases (CVD) are very common conditions and account for significant medical disability and death worldwide. Therefore, their successful management is very critical for the prevention of the significant cardiovascular and socioeconomic consequences arising from their poor management.Areas Covered: Although we have several effective cardiovascular (CV) drugs for their treatment, they are not all completely successful for the effective management of CVD and hypertension. Thus, the need for the discovery and development of new drugs is necessary. For this review, a Medline search of the English language was conducted between 2010 and June 2020 and 62 pertinent papers were retrieved. These papers contain information on newly released and emerging new cardiovascular drugs.Expert opinion These new chemical entities have different mechanisms of action and in preliminary studies have been successful in the treatment of hypertension, CVD, heart failure, stroke, and type 2 diabetes mellitus. These drugs can be used either alone or in combination with other antihypertensive and cardiovascular drugs. Hopefully, these new classes of cardiovascular drugs would be effective for the treatment of hypertension and CVD and decrease their socioeconomic consequences.
No takes yet. Share an insight, caveat, or question.
Chrysant et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: